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Nailfold capillaroscopy in children and 
adolescents with rheumatic diseases
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ABSTRACT
Objective: To assess nailfold capillaroscopy in children and adolescents with autoimmune rheumatic diseases (juvenile 
idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, scleroderma and mixed connective tissue 
disease) and relate it to clinical and laboratory fi ndings and disease activity. Methods: Cross-sectional study assessing 
147 patients by use of nailfold capillaroscopy as follows: 60 with juvenile idiopathic arthritis; 30 with systemic lupus 
erythematosus; 30 with juvenile dermatomyositis; 20 with localized scleroderma; four with systemic sclerosis; and three 
with mixed connective tissue disease. Clinical and laboratory tests and nailfold capillaroscopy were performed in all 
patients. The nailfold capillaroscopy was performed with an optical microscope (at 10- and 16-time magnifi cations) by 
the same observer. Results: Most patients (76.2%) had normal nailfold capillaroscopy. The major changes in nailfold 
capillaroscopy, characterizing the scleroderma pattern, were observed in patients with juvenile dermatomyositis, sys-
temic scleroderma and mixed connective tissue disease. There was no association between nailfold capillaroscopy and 
disease activity in patients with juvenile idiopathic arthritis, systemic lupus erythematosus and localized scleroderma. 
Disease activity and capillaroscopy were associated in patients with juvenile dermatomyositis. Conclusion: Nailfold 
capillaroscopy is a useful method to diagnose autoimmune rheumatic diseases and monitor disease activity.
Keywords: diagnostic equipment, juvenile rheumatoid arthritis, dermatomyositis, child, systemic scleroderma.
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INTRODUCTION
Nailfold capillaroscopy (NFC) plays an important role in the 
assessment of autoimmune rheumatic diseases (AIRD) with 
vascular structural changes. It is easily performed, applicable, 
non-traumatic, and of low cost, being thus useful for the 
diagnosis and follow-up of those diseases. It is also used to 
distinguish primary from secondary Raynaud’s phenomenon 
(RP), to predict the prognosis of AIRD (such as in systemic 
scleroderma – SSc), and to assess disease activity (such as in 
dermatomyositis).1–3 
 NFC has proved to be very useful in the diagnosis of the 
scleroderma spectrum disorders in adults and children. The 
scleroderma pattern (SD-pattern), characterized by capillary 
dilation and avascular areas (vascular deletion), resulting in 
a reduction in the number of capillaries, is found in approxi-
mately 80% of the patients with SSc, but can also be seen in 
patients with dermatomyositis and mixed connective tissue 
disease (MCTD).4–6
 This study aimed at characterizing NFC in children and 
adolescents with AIRD [juvenile idiopathic arthritis (JIA), 
systemic lupus erythematosus (SLE), juvenile dermatomyositis 
(JDM), SSc, and MCTD] and at assessing its relationship to 
clinical and laboratory changes and disease activity.
METHODS
This study assessed 147 children and adolescents cared for at 
the pediatric rheumatology outpatient clinic from March 2008 
to November 2009. It was a convenience sample composed 
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as follows, according to the respective diagnostic or classi-
fi cation criteria:7–12 60 patients with JIA (oligoarticular, 20; 
polyarticular, 20; and systemic, 20); 30 patients with SLE; 30 
patients with JDM; 20 patients with localized scleroderma; 
four patients with SSc; and three patients with DMTC. 
Patients up to the age of 21 years accepting to participate in 
the study and with satisfactory nailfold conditions to undergo 
NFC were included. 
Anamnesis and physical examination were performed on 
the day of NFC, focusing on the following: cutaneous changes 
(skin thickening, Gottron’s sign, heliotrope rash, photo-
sensitivity and periungual hyperemia); calcinosis; digital 
ulcers; RP; arthritis/arthralgia; esophageal and pulmonary 
changes (dysphagia and dyspnea, respectively); assess-
ment of muscle strength in JDM, by use of the Childhood 
Myositis Assessment Scale (CMAS);13 assessment of disease 
activity in JIA,14 in localized scleroderma,15 and in SLE (by 
use of the Systemic Lupus Erythematosus Disease Activity 
Index – SLEDAI).16
Laboratory assessment comprised complete blood count, 
acute-phase tests [erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP)], serum levels of muscle enzymes 
[glutamic-oxaloacetic transaminase (GOT), glutamic-piruvic 
transaminase (GPT), creatine kinase (CK), and lactic de-
hydrogenase (LDH)], autoantibodies [antinuclear antibody 
(ANA), anti-double stranded DNA antibody (anti-ds-DNA), 
extractable nuclear antigen antibody (ENA), rheumatoid fac-
tor (RF), anti-DNA topoisomerase-1 antibody (anti-Scl 70), 
anti-polymyositis-scleroderma antibody (anti-PM-Scl), anti-
cardiolipin immunoglobulin G and immunoglobulin M (ACL 
IgG and ACL IgM, respectively)], and hemolytic complement 
(CH100 and C2). Pulmonary function test (PFT), echocar-
diography and esophagogastroduodenography (EGD) were 
performed in patients with SSc and MCTD.
NFC was performed by the same examiner (MTRAT) 
using an optical microscope (at 10- and 16-time magnifi ca-
tions), equipped with a graded ruler coupled with the right 
objective, allowing counting the number of capillaries per 
millimeter. The patients were instructed not to remove their 
fi ngernail cuticles for one month to avoid microtraumas that 
could jeopardize the exam. The fi ngers were examined (ex-
cept for the thumbs). On semiquantitative analysis, according 
to the method proposed by Andrade et al.,17 the following 
parameters were assessed: integrity of the nailfold; number 
of micro-hemorrhages and their distribution pattern (focal or dif-
fuse); number of capillaries per millimeter; vascular deletion 
score (avascular areas); atypical capillaries, such as dilated, 
‘giant’, crossed, bushy and bizarre capillaries; subpapillary 
venous plexus visualization score; and predominant capil-
lary pattern.17 
Capillaries were considered dilated when the loops were 
widened in all three branches (afferent, transition and ef-
ferent), with calibers ranging from four to nine times the 
normal dimension. ‘Giant’ capillary loops were defi ned as 
extremely widened loops, with calibers 10 or more times 
greater than those of the normal adjacent loops. For re-
cording dilated and ‘giant’ capillaries, the mean number of 
capillaries in each fi nger with those changes was calculated. 
Deletion was defi ned as the absence of two or more suc-
cessive capillaries. To quantify the degree of focal deletion 
or avascular area, a 0–3 scale was used according to the 
extension of the lesions:18 0: no deletion area; 1: one or two 
discontinuous deletion areas; 2: more than two discontinu-
ous deletion areas; 3: extensive and confl uent avascular 
areas. The vascular deletion score was calculated by adding 
the scores of each fi nger and then dividing by the number 
of fi ngers with deletion.
NFC was considered normal in the presence of parallel non-
dysmorphic capillaries and lack of deletion areas. Unspecifi c 
microangiopathy was defi ned as dilated capillaries and other 
morphological changes in the absence of deletion areas. The 
SD-pattern was characterized by dilated or ‘giant’ capillary 
loops and vascular deletion areas. 
All participants provided written informed consent to par-
ticipate in the study, which had been previously approved by 
the Ethics Committee of the Hospital São Paulo.
RESULTS
This study assessed 147 patients by use of NFC. Table 1 shows 
demographic data and the presence of RP. Table 2 shows the 
NFC fi ndings and disease activity of the patients with AIRD. 
Most patients (76.2%) assessed had normal NFC.
Of the 20 patients with oligoarticular JIA, seven (35%) 
showed clinical activity, two (10%) had chronic anterior uve-
itis, and 12 (60%) were positive for ANA. Regarding NFC, all 
patients had normal results. Of the patients with polyarticular 
JIA, fi ve (25%) had RP, seven (35%) were positive for ANA, 
11 (55%) had clinical activity, most patients had normal NFC 
results, and only one patient had unspecifi c microangiopathy. 
Of the patients with systemic JIA, 12 (60%) showed clinical 
activity, 17 (85%) had normal NFC results, one (5%) had un-
specifi c microangiopathy, one (5%) had the SD-pattern, and 
one (5%) was inconclusive due to poor visualization of the 
capillaries. Only two (10%) patients showed capillary tortuos-
ity. No changes on NFC, such as tortuosity, were observed in 
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the oligoarticular and polyarticular subtypes. Twelve (20%) 
patients showed RP, which was associated with NFC changes 
(P = 0.013). In addition, no association of NFC with disease 
activity, presence of RF and ANA was observed in the three 
JIA subtypes (Table 2). 
Of the 30 patients with SLE, six (20%) showed clini-
cal and laboratory activity on the examination. Regarding 
NFC, only two (6.6%) patients showed changes (incipient 
SD-pattern and unspecifi c microangiopathy). Four patients 
positive for anti-RNP showed no changes on NFC. No 
elongated, tortuous, and crossed capillaries were observed. 
Nailfold capillaroscopy associated with neither SLEDAI nor 
RP presence (Table 2).
Of the 30 patients with JDM assessed, 26 (86.6%) were on 
the active phase of the disease. Regarding NFC, 22 of the 26 
exams (84.6%) performed during the active phase of the dis-
ease showed the SD-pattern, while the four exams performed 
during disease remission were normal (P = 0.002) (Table 2). 
Thus, in 26 of the 30 patients (86.6%) assessed, the clinical 
and laboratory data were associated with the NFC fi ndings. No 
association was observed between the NFC results and cuta-
neous changes, muscle weakness, increased levels of muscle 
enzymes, or acute phase tests. 
Regarding NFC fi ndings, the deletion score and number of 
dilated and bushy capillaries were statistically greater in the 
group with active disease (P = 0.004, P = 0.001, P = 0.009, 
respectively). No association was observed between the 
deletion score, number of dilated bushy capillaries and 
megacapillaries, and cutaneous and muscular changes, when 
the variables were assessed separately. The capillaroscopic 
changes and their association with disease activity are shown 
in Table 3.
Table 2
Nailfold capillaroscopy and disease activity in patients with autoimmune rheumatic diseases (n = 147)
JIA
n = 60 
SLE 
n = 30 
JDM 
n = 30 
LSc 
n = 20
SSc 
n = 4 
MCTD 
n = 3 
Normal, n (%) 56 (93.3) 28 (93.4) 8 (26.7) 20 (100) 0 0
Unspeciﬁ c microangiopathy, n(%) 2 (3.3) 1 (3.3) 0 0 0 0
SD-pattern, n (%) 1 (1.7) 1 (3.3) 22 (73.3) 0 3 (75) 3(100)
Inconclusive, n (%) 1 (1.7) 0 0 0 1 (25) 0
Disease activity, n (%) 30 (50) 6 (20) 26 (86.6) 7 (35) 4(100) 3 (100)
P 0.249 0.730 0.002 — — —
JIA: juvenile idiopathic arthritis; SLE: systemic lupus erythematosus; JDM: juvenile dermatomyositis; LSc: localized scleroderma; SSc: systemic scleroderma; MCTD: mixed connective tissue disease.
Table 3
Distribution of the patients with juvenile dermatomyositis 
according to capillaroscopic changes and disease activity 
Capillaroscopic changes
(mean)
Active disease
(n = 26)
Inactive disease
(n = 4) P
N. micro-hemorrhages+ 2.15 2.5 0.677
N. capillary dilation++ 1.77 0.12 0.001*
N. megacapillaries++ 0.18 0 0
N. bushy capillaries++ 0.45 0.03 0.009*
Deletion score+++ 2.06 0.5 0.004*
*Student t test. +Sum of the number of hemorrhages/number of ﬁ ngers with hemorrhage; ++Sum 
of the number of changes/total number of ﬁ ngers assessed; +++Sum of the deletion score/number of 
ﬁ ngers with deletion.
Table 1
Demographic data and presence of Raynaud’s phenomenon in patients with autoimmune rheumatic diseases (n = 147)
Variables JIA n = 60 
SLE 
n = 30 
JDM 
n = 30 
LSc 
n = 20
SSc 
n = 4 
MCTD 
n = 3 
Female gender, n (%) 32 (53.3) 25 (83.3) 20 (66.6) 12 (60) 4 (100) 0
Caucasian race, n (%) 42 (70) 23 (76.7) 23 (76.7) 19 (95.0) 4 (100) 3 (100)
Current age (years), mean ± SD 11.5 ± 4.7 14.4 ± 3.3 10.7 ± 3.6 12.1± 3.3 11.2 ± 5.5 13.7 ± 1.5
Disease duration (years), mean ± SD 6.2 ± 4.3 4.4 ± 2.7 4.0 ± 3.3 5.5 ± 3.3 5.3 ± 3.6 8.7 ± 4.0
Raynaud’s phenomenon, n (%) 12 (20) 11 (36.6) 6 (20) 8 (40) 4 (100) 3 (100)
JIA: juvenile idiopathic arthritis; SLE: systemic lupus erythematosus; JDM: juvenile dermatomyositis; LSc: localized scleroderma; SSc: systemic scleroderma; MCTD: mixed connective tissue disease.
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All 20 patients with localized scleroderma had normal 
NFC. No association with disease activity was observed. 
Four patients with SSc were assessed. On clinical exam, 
all had RP, cutaneous thickening and sclerodactyly. Three 
(75%) had healed digital ulcers. No patient had fever, dys-
pnea, arthritis, or arthralgia. Two female patients reported 
dysphagia and had changes on EGD, and, on lung computed 
tomography, pulmonary fi brosis. All echocardiographies 
performed were normal. Three of four (75%) children 
showed the SD-pattern with reduced capillary density, se-
vere capillary deletion, and ‘giant’ and dilated capillaries. 
In one female patient, NFC could not be performed because 
of poor visualization of the capillaries due to important 
skin thickening.
Three patients diagnosed with MCTD were assessed. All 
underwent echocardiography, PFT and EGD, which resulted 
normal. On NFC, the SD-pattern was observed with reduced 
capillary density, severe deletion and few dilated capillaries. 
All patients had active disease.
DISCUSSION
NFC has proved to be very useful for the diagnosis of the AIRD 
of the scleroderma spectrum. The SD-pattern is considered 
highly specifi c and sensitive to the diagnosis of SSc, being 
found in up to 80% of the patients, but can also be seen in 
patients with dermatomyositis and MCTD.4–6
The SD-pattern has not been described in JIA.19 Only 
non-specifi c changes, such as capillary tortuosity and elon-
gation, increased subpapillary venous plexus visualization, 
and micro-petechiae, can be found. Those changes are more 
often found in patients with polyarticular JIA and positive 
for RF and ANA.19,20 In our study, those changes were not 
found, maybe because of the small amount of patients 
with those antibodies. However, patients with RP show 
more changes on NFC, indicating that they probably have 
vasculopathy. 
SLE is a multisystemic disease that can affect all organs 
in the body. Vascular lesions are the pathological markers 
of that condition and comprise hemorrhages, digital infarc-
tions, and cutaneous lesions. Several authors have described 
unspecifi c changes on NFC, such as elongated, tortuous, and 
crossed capillaries in approximately 30% of those patients. 
Such fi ndings do not depend on the presence of the RP.21–23 
Reduced capillary density and increased capillary diameters 
occur more frequently in individuals with the RP.24 The 
SD-pattern is rare and described in 5%–10% of the patients 
with SLE. In our study no elongated, tortuous, and crossed 
capillaries were found; however, the NFC changes (SD-
pattern and unspecifi c microangiopathy) were associated 
with the RP, as reported in the literature. In a study with 
children and adults, the SLEDAI and presence of anti-RNP 
antibodies were associated with changes on NFC.25 In our 
study the four patients positive for anti-RNP showed no 
changes on NFC.
In JDM the SD-pattern is present in approximately 60% 
of the pateints.6 Although usually undistinguishable from the 
changes found in scleroderma, the microangiopathy of der-
matomyositis shows more bushy capillaries, with exuberant 
branching.26 In addition, the changes seen in dermatomyosi-
tis usually have a more dynamic character than those from 
scleroderma, and can rapidly subside with disease control, 
as seen in our study. Several studies have reported that the 
intensity of the morphological changes on NFC correlate with 
the clinical course and the more severe forms of disease, such 
as ulcerative complications and calcinosis.27–30 In our study, 
disease activity was associated with capillaroscopic changes, 
indicating that NFC is an adequate method to monitor the 
course of JDM.
SSc is characterized by autoimmune changes, mi-
crovascular abnormalities and fibrosis of the skin and 
internal organs. The early diagnosis and assessment of the 
manifestations that indicate disease activity are not always 
easy to obtain; thus, NFC is a method that allows the early 
detection of microvascular changes, characterized in 90% 
of the patients as the SD-pattern.5,31 All our patients with 
SSc had the SD-pattern on NFC. An association with more 
severe deletion on NFC, pulmonary fi brosis, and digital 
ulcers in adults has been reported.32–34 However, because 
of the small number of patients, we could not assess that 
association in children.
Localized (cutaneous) scleroderma usually shows no 
changes on NFC, as reported in our study.35 A study with 27 
adults with localized scleroderma has reported that the only 
two patients with SD-pattern changes on NFC progressed to 
SSc.36 In our study no patient progressed to the systemic form 
of the disease.
On NFC, MCTD shows the SD-pattern in approximately 
60% of the adults.31 Most of those patients develop scleroder-
mic manifestations.35 So far, studies have not been conducted 
with children. In our cohort all patients had the SD-pattern 
on NFC.
NFC proved to be an important method to aid the diagnosis 
of AIRD with vascular structural changes. It was also useful to 
Piotto et al.
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assess disease activity in JDM. Because it is relatively simple, 
easily performed and provides valuable information, the ben-
efi ts easily overcome the costs. However, full training with 
an expert is required. Although the diagnostic criteria do not 
include NFC, it is a complementary and useful test to assess the 
microcirculation of patients, being, thus, one more tool, along 
with clinical and laboratory fi ndings, to aid rheumatologists 
in diagnosing AIRD. 
Capilaroscopia periungueal em crianças e adolescentes com doenças reumáticas
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